A Systematic Review and Meta-Analysis of Inpatient Mortality Associated With Nosocomial and Community COVID-19 Exposes the Vulnerability of Immunosuppressed Adults

Abstract

BackgroundLittle is known about the mortality of hospital-acquired (nosocomial) COVID-19 infection globally. We investigated the risk of mortality and critical care admission in hospitalised adults with nosocomial COVID-19, relative to adults requiring hospitalisation due to community-acquired infection.MethodsWe systematically reviewed the peer-reviewed and pre-print literature from 1/1/2020 to 9/2/2021 without language restriction for studies reporting outcomes of nosocomial and community-acquired COVID-19. We performed a random effects meta-analysis (MA) to estimate the 1) relative risk of death and 2) critical care admission, stratifying studies by patient cohort characteristics and nosocomial case definition.Results21 studies were included in the primary MA, describing 8,251 admissions across 8 countries during the first wave, comprising 1513 probable or definite nosocomial COVID-19, and 6738 community-acquired cases. Across all studies, the risk of mortality was 1.3 times greater in patients with nosocomial infection, compared to community-acquired (95% CI: 1.005 to 1.683). Rates of critical care admission were similar between groups (Relative Risk, RR=0.74, 95% CI: 0.50 to 1.08). Immunosuppressed patients diagnosed with nosocomial COVID-19 were twice as likely to die in hospital as those admitted with community-acquired infection (RR=2.14, 95% CI: 1.76 to 2.61).ConclusionsAdults who acquire SARS-CoV-2 whilst already hospitalised are at greater risk of mortality compared to patients admitted following community-acquired infection; this finding is largely driven by a substantially increased risk of death in individuals with malignancy or who had undergone transplantation. These findings inform public health and infection control policy and argue for individualised clinical interventions to combat the threat of nosocomial COVID-19, particularly for immunosuppressed groups.Systematic Review RegistrationPROSPERO CRD42021249023

Mortality trends and lengths of stay among hospitalized COVID-19 patients in Ontario and Québec (Canada): a population-based cohort study of the first three epidemic waves

“…Overall, our analyses suggest that part of these in-hospital mortality risk reductions could be sustained if hospital capacity is maintained and hospital-acquired infections are prevented. These findings are aligned with those from studies conducted worldwide 14,25,40-42 . Limited critical care resources and rapidly increasing staff-to-patient ratio could have influenced patient outcomes during periods of high transmission 29,43 .…”

“…Limited critical care resources and rapidly increasing staff-to-patient ratio could have influenced patient outcomes during periods of high transmission 29,43 . Additionally, nosocomial infections could exacerbate mortality risk because the already admitted patient population has vulnerable health conditions and higher rates of comorbidities 42,44 .…”

Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients

“…A number of studies have confirmed that immunocompromised patients are at high risk of developing severe COVID-19 disease and of dying when infected with SARS-CoV-2 (65)(66)(67)(68). This seems to be particularly the case in patients with combined defects of B and T cell immunity as observed early after transplantation as well as in patients given intensive chemotherapy (69)(70)(71)(72)(73).…”

Evaluating the effectiveness of rapid SARS-CoV-2 genome sequencing in supporting infection control teams: the COG-UK hospital-onset COVID-19 infection study

“…Throughout the pandemic, nosocomial transmission of SARS-CoV-2 has been a major concern [5] , with hospital-acquired infections (HAIs) accounting for more than 5% of lab-confirmed cases from March-August 2020 in the UK [6] and representing 11% of COVID-19 cases within hospitals in this period [7] . HAIs also frequently occur within a very vulnerable population with high levels of mortality [6, 8, 9] . There is therefore an unmet need to develop interventions that can reduce the occurrence of nosocomial transmission.…”